Evidence map›Paper›PMID 41303378›Full record

ArticleInternational journal of molecular sciences2025

Clofazimine Treatment Modulates Key Non-Coding RNAs Associated with Tumor Progression and Drug Resistance in Lethal Prostate Cancer.

Sarah Batten, Harish Kumar, Jeremiah Pfitzer, Daniel Chinedu Nweze, Suman Mazumder, Robert D Arnold, Panagiotis Mistriotis, Taraswi Mitra Ghosh, Amit Kumar Mitra

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sarah BattenDepartment of Drug Discovery & Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA.ORCID 0009-0007-9854-9091
Harish KumarDepartment of Drug Discovery & Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA.
Jeremiah PfitzerDepartment of Drug Discovery & Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA.ORCID 0000-0002-0785-8312
Daniel Chinedu NwezeDepartment of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, Auburn, AL 36849, USA.
Suman MazumderDepartment of Drug Discovery & Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA.
Robert D ArnoldDepartment of Drug Discovery & Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA.ORCID 0000-0001-6143-3991
Panagiotis MistriotisDepartment of Chemical Engineering, Samuel Ginn College of Engineering, Auburn University, Auburn, AL 36849, USA.ORCID 0000-0002-8069-3278
Taraswi Mitra GhoshDepartment of Urology, Mass General Brigham and Women's Hospital, 1529 Thorn Research Building, 20 Shattuck Street, Boston, MA 02115, USA.
Amit Kumar MitraDepartment of Drug Discovery & Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA.ORCID 0000-0003-4046-7070

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic castration-resistant prostate cancer/PCa (mCRPC) is a clinically advanced form of PCa that is associated with increased aggressiveness, cancer stemness, morbidity, and the risk of developing resistance to taxanes, currently the first-line chemotherapy for mCRPC. Clofazimine (CLF) is a potential immunomodulator drug that is FDA-approved for the treatment of leprosy. Recently, using

Indexed as

ClofazimineDrug Resistance, NeoplasmProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantRNA, UntranslatedApoptosisCell Line, TumorCell MovementCell ProliferationDisease ProgressionEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansMaleNeoplastic Stem CellsClofazimineRNA, Untranslatedclofaziminecombination therapylncRNAmCRPCnon-coding RNARNAseqtaxane resistance

Identifiers

PMID41303378
PMCPMC12652201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.